Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Jorge Correale1 Department of Neurology, Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses (FLENI), Buenos Aires, ArgentinaCorrespondence[email protected]

Erwin Chiquete2 Department of Neurology and Psychiatry, Salvador Zubirán National Institute of Medical Sciences and Nutrition, Mexico City, Mexico

Alexey Boyko3 Clinical and Research Center “MS and Other Demyelinating Diseases” at the Neuroclinical Hospital, Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University, Moscow, Russia

Roy G Beran4 South Western Clinical School, University of New South Wales, Liverpool;5 Department of Neurology, Liverpool Hospital, Sydney, NSW;6 School of Medicine, Griffith University, Southport, QLD, Australia

Jorge Barahona Strauch7 Department of Neurology, Clínica Alemana de Santiago;8 School of Medicine, Universidad del Desarrollo, Santiago, Chile

Snezana Milojevic9 Novartis Pharma AG, Basel, Switzerland

Nadina Frider10 Novartis Latin America and Canada Region, Buenos Aires, Argentina

show all

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date